First-line treatment in HIV: many paths to success.
Cohen
Calvin
C
CRI New England, Harvard Vanguard Medical Associates, and Harvard Medical School, Boston, Massachusetts, USA.
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D024921:Drug Resistance, Multiple, Viral; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors